PDF(Pubmed)
Abstract：
BACKGROUND: Allergic rhinitis (AR) is a major non-communicable disease that affects the health-related quality of life (HRQoL) of patients. However, data on HRQoL and symptom control in AR patients with comorbid asthma (AR + asthma) are lacking.
METHODS: In this multicentre, cross-sectional study, patients with AR were screened and administered questionnaires of demographic characteristics and health conditions (symptoms/diagnosis of AR and asthma, disease severity level, and allergic conditions). HRQoL was assessed using a modified version of the RHINASTHMA questionnaire (30, \'not at all bothered\' - 150 \'very much bothered\') and symptom control was evaluated by a modified version of the Control of Allergic Rhinitis/Asthma Test (CARAT) (0, \'no control\' - 30, \'very high control\').
RESULTS: Out of 643 patients with AR, 500 (78%) had asthma as a comorbidity, and 54% had moderate-severe intermittent AR, followed by moderate-severe persistent AR (34%). Compared to the patients with AR alone, patients with AR + asthma had significantly higher RHINASTHMA (e.g., median RHINASTHMA-total score 48.5 vs. 84, respectively) and a significantly lower CARAT score (median CARAT-total score 23 vs. 16.5, respectively). Upon stratifying asthma based on severity, AR patients with severe persistent asthma had worse HRQoL and control than those with mild persistent asthma. The association was significantly higher among non-obese participants compared to obese ones, with RHINASTHMA-upper symptoms score but not with CARAT.
CONCLUSIONS: Our observation of poorer HRQoL and symptoms control in AR patients with comorbid asthma supports the importance of a comprehensive approach for the management of AR in case of a comorbid allergic condition.
METHODS: In this multicentre, cross-sectional study, patients with AR were screened and administered questionnaires of demographic characteristics and health conditions (symptoms/diagnosis of AR and asthma, disease severity level, and allergic conditions). HRQoL was assessed using a modified version of the RHINASTHMA questionnaire (30, \'not at all bothered\' - 150 \'very much bothered\') and symptom control was evaluated by a modified version of the Control of Allergic Rhinitis/Asthma Test (CARAT) (0, \'no control\' - 30, \'very high control\').
RESULTS: Out of 643 patients with AR, 500 (78%) had asthma as a comorbidity, and 54% had moderate-severe intermittent AR, followed by moderate-severe persistent AR (34%). Compared to the patients with AR alone, patients with AR + asthma had significantly higher RHINASTHMA (e.g., median RHINASTHMA-total score 48.5 vs. 84, respectively) and a significantly lower CARAT score (median CARAT-total score 23 vs. 16.5, respectively). Upon stratifying asthma based on severity, AR patients with severe persistent asthma had worse HRQoL and control than those with mild persistent asthma. The association was significantly higher among non-obese participants compared to obese ones, with RHINASTHMA-upper symptoms score but not with CARAT.
CONCLUSIONS: Our observation of poorer HRQoL and symptoms control in AR patients with comorbid asthma supports the importance of a comprehensive approach for the management of AR in case of a comorbid allergic condition.
摘要：
背景：过敏性鼻炎（AR）是一种主要的非传染性疾病，会影响患者与健康相关的生活质量（HRQoL）。然而,缺乏AR合并哮喘(AR+哮喘)患者的HRQoL和症状控制数据.
方法：在这个多中心中，横断面研究，对AR患者进行了筛查，并进行了人口统计学特征和健康状况调查问卷（AR和哮喘的症状/诊断，疾病严重程度,和过敏状况)。HRQoL使用改良版本的RHINATHMA问卷进行评估（30，“一点都不困扰”-150，“非常困扰”），症状控制通过改良版本的变应性鼻炎控制/哮喘测试（CARAT）进行评估（0，“无控制”-30，“控制非常高”）。
结果：在643例AR患者中，500人（78%）患有哮喘共病，54%有中度-重度间歇性AR，其次是中重度持续性AR（34%）。与单纯AR患者相比，AR+哮喘患者的哮喘明显较高(例如，RHINATHMA-总分中位数48.5vs.84）和显著较低的CARAT评分（CARAT总分中位数23vs.16.5，分别）。根据严重程度对哮喘进行分层后，与轻度持续性哮喘患者相比，重度持续性哮喘患者的HRQoL和控制较差。与肥胖参与者相比，非肥胖参与者的关联性明显更高，伴有鼻炎-上肢症状评分，但不伴有CARAT。
结论：我们对合并哮喘的AR患者的HRQoL和症状控制较差的观察结果支持了在合并过敏性疾病的情况下采用综合方法治疗AR的重要性。
方法：在这个多中心中，
结果：在643例AR患者中，
结论：我们对合并哮喘的AR患者的HRQoL和症状控制较差的观察结果支持了在合并过敏性疾病的情况下采用综合方法治疗AR的重要性。
